CAS: 374537-95-8; Methyl 3-(4-(Chlorosulfonyl)Phenyl)Propanoate

上下游产品

CAS号103-25-3 3-苯丙酸甲酯

📜3-苯丙酸甲酯置于氯磺酸体系中,用 二氯甲烷 用作溶剂,化学反应 3.0H,反应生成3-(4-磺酰氯)苯丙酸甲酯
参考文献:二苯基烷基恶二唑类新型心肌肌球蛋白激活剂的探索
标题:二苯基烷基恶二唑类新型心肌肌球蛋白激活剂的探索
摘要:为了探索新型的心肌肌球蛋白活化剂,已经制备了一系列的二苯烷基取代的1,3,4-恶二唑和1,2,4-恶二唑,并在体外测试了心脏肌球蛋白atp酶的活化.在所有情况下,在恶二唑核和苯环之一之间的三个碳间隔基被认为是至关重要的.在1,3,4-恶二唑的情况下,恶二唑核与其他苯环之间的零至两个碳间隔是有利的.苯环可以被环己基部分取代.在1,2,4-恶二唑的情况下,恶二唑与其他苯环之间的零或一个碳间隔基是有利的.在2氢键供体(nh)基团的引入第二1,3,4-恶二唑的位置增强了活性.两种恶二唑均不能耐受任何一个苯环上的取代或苯环上的取代成其他杂环.所制备的恶二唑在平滑肌和骨骼肌上显示出对心肌的选择性激活.
Doi:10.1016/j.Bmcl.2018.06.031

专利信息

专利号:US-2008194629-A1
优先权日:2005-05-03
标题 :3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors
发明人：BAESCHLIN DANIEL KASPAR; BREITENSTEIN WERNER; EHRHARDT CLAUS; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; ZIMMERMANN JUERG; RUDISSER SIMON; VANGREVELINGHE ERIC; IRIE OSAMU; UMEMURA ICHIRO; SUZUKI MASAKI; MOGI MUNETO; KANAZAWA TAKANORI; YOKOKAWA FUMIAKI; NIHONYANAGI ATSUKO
权利人:BAESCHLIN DANIEL KASPAR; BREITENSTEIN WERNER; EHRHARDT CLAUS; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; ZIMMERMANN JUERG; RUDISSER SIMON; VANGREVELINGHE ERIC; IRIE OSAMU; UMEMURA ICHIRO; SUZUKI MASAKI; MOGI MUNETO; KANAZAWA TAKANORI; YOKOKAWA FUMIAKI; NIHONYANAGI ATSUKO
摘要:The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-piperidine compound, and/or a method of treatment comprising administering a 3,5-piperidine compound, a method for the manufacture of a 3,5-piperidine compound, and novel intermediates and partial steps for their synthesis. Especially, the 3,5-piperidine compounds have the formula I, wherein the symbols have the meanings described in the specification.